[2 new proton pump inhibitors. Possibilities of pantoprazole and lansoprazole].
Leonhardt
U
U
Abteilung Gastroenterologie und Endokrinologie, Georg-August-Universität, Göttingen.
Ritzel
U
U
Ramadori
G
G
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D064747:Lansoprazole; D009853:Omeprazole / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D000077402:Pantoprazole; D010437:Peptic Ulcer / Q000097:blood / Q000188:drug therapy*; D013329:Structure-Activity Relationship; D013454:Sulfoxides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D001562:Benzimidazoles; D013454:Sulfoxides; D064747:Lansoprazole; D000077402:Pantoprazole; D009853:Omeprazole
Zwei neue Protonenpumpenhemmer. Möglichkeiten von Pantoprazol und Lansoprazol.